UBS Group
ABEO icon

UBS Group’s Abeona Therapeutics ABEO Stock Holding History

UBS Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
223,279
-10,645
-5% -$58.4K ﹤0.01% 5442
2026
Q1 		$1.05M Buy
233,924
+73,523
+46% +$368K ﹤0.01% 5523
2025
Q4 		$845K Buy
160,401
+32,169
+25% +$162K ﹤0.01% 5716
2025
Q3 		$677K Buy
128,232
+11,290
+10% +$71.6K ﹤0.01% 5869
2025
Q2 		$664K Buy
116,942
+17,623
+18% +$100K ﹤0.01% 5777
2025
Q1 		$473K Buy
99,319
+36,322
+58% +$198K ﹤0.01% 5894
2024
Q4 		$351K Buy
+62,997
New +$388K ﹤0.01% 6090
2024
Q3 		– Sell
-3,000
Closed -$12.7K – 9441
2024
Q2 		$12.7K Sell
3,000
-7,457
-71% -$38K ﹤0.01% 7586
2024
Q1 		$75.8K Buy
+10,457
New +$66.3K ﹤0.01% 6336
2023
Q4 		– Sell
-1,061
Closed -$4.47K – 9226
2023
Q3 		$4.47K Sell
1,061
-44
-4% -$167 ﹤0.01% 7441
2023
Q2 		$4.45K Buy
+1,105
New +$3.87K ﹤0.01% 7531
2023
Q1 		– Sell
-967
Closed -$2.98K – 9527
2022
Q4 		$2.98K Buy
+967
New +$3.62K ﹤0.01% 9588
2022
Q3 		– Sell
-1,773
Closed -$9K – 10262
2022
Q2 		$9K Buy
1,773
+611
+53% +$3.09K ﹤0.01% 8107
2022
Q1 		$9K Sell
1,162
-246
-17% -$1.69K ﹤0.01% 8526
2021
Q4 		$12K Buy
1,408
+1,224
+665% +$22.5K ﹤0.01% 8539
2021
Q3 		$5K Sell
184
-234
-56% -$7.49K ﹤0.01% 8507
2021
Q2 		$16K Sell
418
-227
-35% -$9.26K ﹤0.01% 7557
2021
Q1 		$30K Sell
645
-152
-19% -$8.37K ﹤0.01% 7006
2020
Q4 		$31K Buy
797
+345
+76% +$11.8K ﹤0.01% 6593
2020
Q3 		$12K Sell
452
-632
-58% -$39.8K ﹤0.01% 6686
2020
Q2 		$79K Sell
1,084
-186
-15% -$12.9K ﹤0.01% 5488
2020
Q1 		$67K Sell
1,270
-386
-23% -$25.8K ﹤0.01% 5592
2019
Q4 		$135K Buy
1,656
+636
+62% +$44.9K ﹤0.01% 5844
2019
Q3 		$58K Buy
1,020
+604
+145% +$45.2K ﹤0.01% 6111
2019
Q2 		$50K Buy
416
+410
+6,833% +$68.7K ﹤0.01% 5922
2019
Q1 		$1K Sell
6
-596
-99% -$107K ﹤0.01% 7515
2018
Q4 		$108K Sell
602
-733
-55% -$160K ﹤0.01% 5463
2018
Q3 		$427K Buy
1,335
+1,275
+2,125% +$452K ﹤0.01% 4524
2018
Q2 		$24K Sell
60
-6,023
-99% -$2.63M ﹤0.01% 6561
2018
Q1 		$2.18M Buy
6,083
+1,627
+37% +$604K ﹤0.01% 3062
2017
Q4 		$1.77M Sell
4,456
-386
-8% -$160K ﹤0.01% 3295
2017
Q3 		$2.06M Buy
4,842
+4,780
+7,710% +$1.28M ﹤0.01% 3102
2017
Q2 		$10K Buy
+62
New +$8.46K ﹤0.01% 6762
2017
Q1 		– Hold
0
– – – 7587
2016
Q4 		– Hold
0
– – – 7738
2016
Q3 		– Hold
0
– – – 7632
2016
Q2 		– Hold
0
– – – 7678
2016
Q1 		– Sell
-23
Closed -$1.52K – 7572
2015
Q4 		$2K Buy
+23
New +$2.31K ﹤0.01% 7986
2015
Q3 		– Hold
0
– – – 8365
2015
Q2 		– Hold
0
– – – 8441
2015
Q1 		– Hold
0
– – – 8714
2014
Q4 		– Hold
0
– – – 9671

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's ABEO Position: Q2 2026 in Review

UBS Group reduced its Abeona Therapeutics (ABEO) stake by 4.6% in Q2 2026, selling an estimated $58.4K and leaving 223,279 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #5442.

UBS Group first reported a position in ABEO in Q4 2015 and has held it in 34 quarters since. The position peaked at $2.18M in Q1 2018. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • UBS Group held 223,279 shares of Abeona Therapeutics worth $1.38M as of Q2 2026.
  • UBS Group sold 10,645 Abeona Therapeutics shares in Q2 2026, an estimated $58.4K.
  • Abeona Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5442 holding.
  • UBS Group first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 34 quarters since.
  • UBS Group's Abeona Therapeutics position peaked at $2.18M in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.